|
1
|
[The place of Glitazones in the treatment of diabetes: after the PROactive study].
|
Ugeskr Laeger
|
2006
|
1.38
|
|
2
|
Smoking as a risk factor for Graves' disease, toxic nodular goiter, and autoimmune hypothyroidism.
|
Thyroid
|
2002
|
1.05
|
|
3
|
The Danish Centre for Strategic Research in Type 2 Diabetes (DD2) Project: rationale and planned nationwide studies of genetic predictors, physical exercise, and individualized pharmacological treatment.
|
Clin Epidemiol
|
2012
|
0.99
|
|
4
|
Survival following a metformin overdose of 63 g: a case report.
|
Pharmacol Toxicol
|
2003
|
0.99
|
|
5
|
SLC30A3 responds to glucose- and zinc variations in beta-cells and is critical for insulin production and in vivo glucose-metabolism during beta-cell stress.
|
PLoS One
|
2009
|
0.99
|
|
6
|
Zinc-transporter genes in human visceral and subcutaneous adipocytes: lean versus obese.
|
Mol Cell Endocrinol
|
2006
|
0.96
|
|
7
|
Zinc transporter gene expression is regulated by pro-inflammatory cytokines: a potential role for zinc transporters in beta-cell apoptosis?
|
BMC Endocr Disord
|
2009
|
0.94
|
|
8
|
Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer´s disease - protocol for a controlled, randomized double-blinded trial.
|
Dan Med J
|
2012
|
0.89
|
|
9
|
Antidiabetic treatments and risk of hospitalisation with myocardial infarction: a nationwide case-control study.
|
Pharmacoepidemiol Drug Saf
|
2011
|
0.89
|
|
10
|
Glucagon-like peptide-1 decreases intracerebral glucose content by activating hexokinase and changing glucose clearance during hyperglycemia.
|
J Cereb Blood Flow Metab
|
2012
|
0.88
|
|
11
|
Glucagon-like peptide-1 inhibits blood-brain glucose transfer in humans.
|
Diabetes
|
2007
|
0.88
|
|
12
|
Role of nonalcoholic fatty liver disease in the development of insulin resistance and diabetes.
|
Expert Rev Gastroenterol Hepatol
|
2008
|
0.88
|
|
13
|
Zinc, alpha cells and glucagon secretion.
|
Curr Diabetes Rev
|
2010
|
0.88
|
|
14
|
Differences between long-acting insulins for the treatment of type 2 diabetes.
|
Expert Opin Pharmacother
|
2010
|
0.87
|
|
15
|
Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study.
|
Diabetes Metab Res Rev
|
2009
|
0.86
|
|
16
|
At the centennial of Michaelis and Menten, competing Michaelis-Menten steps explain effect of GLP-1 on blood-brain transfer and metabolism of glucose.
|
Basic Clin Pharmacol Toxicol
|
2014
|
0.86
|
|
17
|
Calcineurin inhibitors acutely improve insulin sensitivity without affecting insulin secretion in healthy human volunteers.
|
Br J Clin Pharmacol
|
2012
|
0.85
|
|
18
|
Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes.
|
Expert Opin Ther Targets
|
2011
|
0.84
|
|
19
|
Chemical blocking of zinc ions in CNS increases neuronal damage following traumatic brain injury (TBI) in mice.
|
PLoS One
|
2010
|
0.84
|
|
20
|
Glucagon-like peptide-1 (GLP-1) raises blood-brain glucose transfer capacity and hexokinase activity in human brain.
|
Front Neuroenergetics
|
2013
|
0.83
|
|
21
|
Serum ghrelin levels are increased in hypothyroid patients and become normalized by L-thyroxine treatment.
|
J Clin Endocrinol Metab
|
2008
|
0.83
|
|
22
|
Type of preadmission antidiabetic treatment and outcome among patients with ischemic stroke: a nationwide follow-up study.
|
J Stroke Cerebrovasc Dis
|
2011
|
0.82
|
|
23
|
Sulfonylureas and the risk of myocardial infarction.
|
Metabolism
|
2006
|
0.82
|
|
24
|
ZnT3: a zinc transporter active in several organs.
|
Biometals
|
2011
|
0.80
|
|
25
|
Gastrointestinal and systemic uptake of bismuth in mice after oral exposure.
|
Pharmacol Toxicol
|
2003
|
0.80
|
|
26
|
siRNA-mediated knock-down of ZnT3 and ZnT8 affects production and secretion of insulin and apoptosis in INS-1E cells.
|
APMIS
|
2010
|
0.80
|
|
27
|
Metallic gold slows disease progression, reduces cell death and induces astrogliosis while simultaneously increasing stem cell responses in an EAE rat model of multiple sclerosis.
|
Histochem Cell Biol
|
2012
|
0.79
|
|
28
|
Effects of zinc supplementation and zinc chelation on in vitro β-cell function in INS-1E cells.
|
BMC Res Notes
|
2014
|
0.78
|
|
29
|
An update on the long-acting insulin analogue glargine.
|
Basic Clin Pharmacol Toxicol
|
2006
|
0.78
|
|
30
|
Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited.
|
Rev Endocr Metab Disord
|
2014
|
0.78
|
|
31
|
Postmenopausal estrogen therapy and risk of gallstone disease: a population-based case-control study.
|
Drug Saf
|
2013
|
0.78
|
|
32
|
Reduced expression of uncoupling protein 2 in adipose tissue in patients with hypothyroidism.
|
J Clin Endocrinol Metab
|
2010
|
0.78
|
|
33
|
Is metformin therapy for polycystic ovary syndrome safe during pregnancy?
|
Basic Clin Pharmacol Toxicol
|
2005
|
0.77
|
|
34
|
Gene expression changes induced by bismuth in a macrophage cell line.
|
Cell Tissue Res
|
2005
|
0.77
|
|
35
|
Gene networks modified by sulphonylureas in beta cells: a pathway-based analysis of insulin secretion and cell death.
|
Basic Clin Pharmacol Toxicol
|
2012
|
0.77
|
|
36
|
Metallic gold beads in hyaluronic acid: a novel form of gold-based immunosuppression? Investigations of the immunosuppressive effects of metallic gold on cultured J774 macrophages and on neuronal gene expression in experimental autoimmune encephalomyelitis.
|
Biometals
|
2013
|
0.77
|
|
37
|
Uptake of silver from metallic silver surfaces induces cell death and a pro-inflammatory response in cultured J774 macrophages.
|
Histol Histopathol
|
2011
|
0.77
|
|
38
|
Lifestyle and clinical factors associated with elevated C-reactive protein among newly diagnosed Type 2 diabetes mellitus patients: a cross-sectional study from the nationwide DD2 cohort.
|
BMC Endocr Disord
|
2014
|
0.76
|
|
39
|
Metallic silver fragments cause massive tissue loss in the mouse brain.
|
Basic Clin Pharmacol Toxicol
|
2011
|
0.76
|
|
40
|
[Successful treatment of diabetic gustatory hyperhidrosis with topical glycopyrrolate].
|
Ugeskr Laeger
|
2011
|
0.76
|
|
41
|
Decreased lipid intermediate levels and lipid oxidation rates despite normal lipolysis in patients with hypothyroidism.
|
Thyroid
|
2010
|
0.76
|
|
42
|
The Danish national type 2 diabetes cohort - the DD2 study.
|
Clin Epidemiol
|
2012
|
0.75
|
|
43
|
Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes.
|
Diabetes Metab Syndr Obes
|
2012
|
0.75
|
|
44
|
Long-term parathyroid- and c-cell function after radioiodine for benign thyroid diseases.
|
Basic Clin Pharmacol Toxicol
|
2005
|
0.75
|
|
45
|
Modifiable clinical and lifestyle factors are associated with elevated alanine aminotransferase levels in newly diagnosed type 2 diabetes patients: results from the nationwide DD2 study.
|
Diabetes Metab Res Rev
|
2014
|
0.75
|
|
46
|
[Sodium-glucose cotransporter 2 (SGLT-2) inhibitors for patients with Type 2 diabetes].
|
Ugeskr Laeger
|
2016
|
0.75
|
|
47
|
[Endocrinological assessment, treatment and follow-up on polycystic ovary syndrome].
|
Ugeskr Laeger
|
2010
|
0.75
|
|
48
|
Decreased serum testosterone levels in rats exposed intraperitoneally to bismuth subnitrate.
|
J Appl Toxicol
|
2002
|
0.75
|
|
49
|
[Patients Disciplinary Board, expert knowledge or legal rights].
|
Ugeskr Laeger
|
2003
|
0.75
|
|
50
|
[In Process Citation].
|
Ugeskr Laeger
|
2014
|
0.75
|
|
51
|
[Vaginal oestrogen therapy in women with hormone-sensitive breast cancer].
|
Ugeskr Laeger
|
2011
|
0.75
|
|
52
|
Exogenous metallothionein potentiates the insulin response at normal glucose concentrations in INS-1E beta-cells without disturbing intracellular ZnT8 expression.
|
Basic Clin Pharmacol Toxicol
|
2014
|
0.75
|